Two doses of the once-daily, oral factor Xa inhibitor edoxaban were noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation in the phase III ENGAGE...

Field of Interest: Cardiology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.